Users Stopping Weight-Loss Medications Regain Pounds Four Times Faster Compared to Those on Conventional Diets

Fresh analysis suggests that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional lifestyle plans.

Published data in a leading health publication demonstrates that while obese people can lose a large proportion of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month after stopping.

"Users using such treatments need to be aware of the potential of fast rebound weight gain when the therapy is stopped," stated expert Dr. Susan Jebb.

Such speed of regain implies a reversion to original weight within about a year and a half.

Comparing Treatments

The analysis, which reviewed 37 of trials involving thousands of participants, compared the effects of these new drugs with conventional dieting.

The team point out that individuals who shed pounds through dieting usually experience a more gradual creep back—around 0.1 kg a month—after stopping.

Understanding the Fast Regain

Doctors believe the way of the injections explains the accelerated weight return.

The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.

"Withdrawal of this medication leads to appetite is no longer kept in check, making overeating much more probable."

An Ongoing Disease?

Medical guidelines recommend the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

Professionals argue that, due to the significant potential of weight regain, the treatment is often life-long.

This view is supported by drug manufacturers, who state that the findings "highlight the long-term character of obesity," akin to managing conditions like hypertension.

Patient Experiences

Users who have stopped the medication describe a powerful return of hunger.

"I experienced a switch flipping and you become starving," described a patient.

This difficulty is exacerbated if individuals have not developed lasting dietary or behavioural changes during treatment.

Widespread Use

Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Adoption is greater among women than males.
• The middle-aged demographic shows the greatest level of interest.
• Many access the medications through private prescriptions rather than public health services.

Ultimately, clinicians stress that while these medications are potent tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle management.